Table 4

Impact of vitamin E on ALT, AST, BMI and steatosis score in trials

Author and yearOutcomes with respect to control and intervention group
ALT (U/L)AST (U/L)BMI (kg/m²)Steatosis score
InterventionControlP valueInterventionControlP valueInterventionControlP valueInterventionControlP value
Harrison et al , 200312 −12.3−310.007**NR−1.1−1.60.012NRNRNR
Vajro et al , 200418 −31.90†
−24.09‡
−26.36†
−29.9
2‡
0.54†
0.6
6‡
NRNRNRNRNRNR**NR
Nobili et al , 200616 −36.35−24.440.0001−13.95−10.050.001−2.39−1.830.0001§§NR
Nobili et al , 200817 −31−290.6−12−150.6−3.7−3.10.4−100.07
Sanyal et al, 201015 −37−20.10.001−21.3−3.8<0.0010.10.40.50−1.026−0.5890.005
Lavine et al, 20116 −48.3−35.20.07−22.8−20.40.32−0.03−0.010.78−0.621−0.3990.18
Foster et al, 201113 *NRNR*NRNRNRNRNRDecreased based on abdominal CT scanNRNR
Hoofnagle et al , 201314 −21.6−5.1NRNRNRNRNRNR−0.7−0.7Vitamin E=<0.001
Placebo=<0.001
Aller et al , 20151 −3.7−16.1<0.05−1−5.6<0.05−5.1−2.9<0.05**NR
  • (−) Improvement in the outcome (mean response value − mean baseline value).

  • *Non-significant.

  • †Evaluation at month 2; this p value indicates difference between control and intervention group.

  • ‡Evaluation at month 5; this p value indicates difference between control and intervention group.

  • §Steatosis was present in all biopsies, mostly macrovesicular, but frequently associated with microvesicular steatosis.

  • ¶Significant improvement.

  • ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; NR, not reported.